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Drug-resistant Plasmodium
falciparum malaria in the
eastern Transvaal
H. E. Deacon, J. A. Freese, B. L. Sharp
In March 1993, a study was undertaken in the
. KomatipoortlMalelane area to monitor the in vitro
sensitivity of Plasmodium falciparum to antimalarial
drugs currently in use in South Africa. Of the 12 isolates
collected, 7 were successfully tested for sensitivity to
chloroquine and quinine, 6 for mefloquine susceptibility,
and 5 for sensitivity to Fansidar. Four of the isolates were
resistant to chloroquine at Rill level, 1 at Rlllevel, and 2
were sensitive. All isolates were found to be sensitive to
both quinine and mefloquine. Results suggested possible
resistance to Fansidar. These findings have implications
for tourists travelling to this area.
S Afr Med J 1994; 84: 394-395.
Resistance to chloroquine was first detected in 1958
in both South America and south-east Asia.'
It was first reported from Africa in 1979, from both Kenya'
and Tanzania.' Reports of in vivo and in vitro resistance to
chloroquine then followed in the 1980s from all the southern
African countries, including Botswana: Mozambique,5
Angola,"'? Namibia,' Zimbabwe· and Swaziland.9 Chloroquine
resistance was first reported in South Africa in 1'985.
Bac et aI. 'O reported on an in vivo resistant case from Venda
which was confirmed in vitro; Visagie and Sieling" reported
on an in vivo case of chloroquine resistance from Louis
Trichardt, and Herbst et al. '2 reported on 6 in vitro
chloroquine-resistant isolates from the KwazululNatal area.
A number of further studies have been completed in
Kwazulul Natal confirming the presence of highly
chloroquine-resistant Plasmodium falciparum. '3-15
Other than some case reports of chloroqUine resistance in
the Transvaal,'o,,, no further published data from in vivo
studies or in vitro tests of field isolates exist for the area.
Freese et al. '6 reported on the in vitro sensitivity of 5
culture-adapted isolates collected in the eastern Transvaal.
Four of the 5 isolates studied were found to be resistant to
chloroquine. Although the culture conditions may have
resulted in the selection of resistant clones in these isolates,
the results of the investigation nevertheless indicated the
presence of chloroquine-resistant parasites in the local
P. falciparum population.
National Malaria Research Programme of the South African
Medical Research Council (Natal), Durban
H. E. Deacon. B.SC. HONS
J. A. Freese. 8.SC. HONS
B. L Sharp. PHD.
It should be borne in mind that more than 40% of cases
are classified as imported into the eastern and northern
Transvaal provinces, of which a high percentage originate
from other southern African countries where drug resistance
is known to occur (Department of National Health and
Population Development - notification data).
The South African Medical Research Council recently
initiated an investigation into the drug susceptibility of P.
falciparum in the Transvaal area. In a survey carried out in
March 1993 in the KomatipoortlMalelane area of the eastern
Transvaal, the in vitro sensitivity of P. falciparum to
antimalarial drugs currently in use in South Africa was
monitored.
Materials and methods
Blood containing P. falciparum was obtained from patients
reporting to local clinics and doctors in the area (Le. .:
passively detected cases)" and tested within 6 hours of
collection for sensitivity to chloroquine, quinine, mefloqoine
and sUlphadoxine/pyrimethamine (Fansidar), using a
modification of the WHO in vitro microtechnique.14
Isolates were considered to be suitable for the test if they
contained 500 - 80 000 ring forms of P. falciparum per
microlitre blood. Patients with mixed malarial infections and
those who had received antimalarial drugs during the 14
days prior to the test were excluded from the investigation.
The minimum inhibitory concentration (MIC) of each
isolate, defined as the lowest concentration at which
schizont maturation (SM) was completely inhibited, was
determined for each drug. The discriminating MICs'for
resistant isolates are: chloroquine> 0,16 j.Lmol/l, quinine>
5,12 j.Lmol/l, and mefloquine > 0,64 j.LmoVI.'6
Results
Of the 12 isolates found to be suitable for the test, 7 were
successfully tested for sensitivity to chloroquine and quinine,
6 for mefloquine susceptibility, and 5 for sensitivity to
Fansidar. Four of the isolates were resistant to chloroquin~
at Rill level (with MICs ranging from 0,64 to 1,28 j.Lmol/l); 1
at RII level (MIC 0,32 j.LmoVI);' and 2 were sensitive (MICs
0,04 and 0,16 j.Lmol/l) (Table I). All isolates were found to be
sensitive to both quinine (MIC 1,28 j.Lmol/1 for all 7 isolates)
and mefloquine (MICs ranging from 0,04 to 0,16 j.LmoVI).
The Fansidar MICs ranged from 0,2 to 60 j.LmoVI.
Table I. In vitro sensitivity of eastern Transvaal isolates of
Plasmodium falciparum to four antimalarial drugs
Isolate Chloroquine Quinine Mefloquine Fansidar
No. MIC (IJmoVl) MIC (IJmoVl) MIC (IJmol/l) MIC (IJmoVl)
1 0,32 1,28 NS NS
5 1,28 1,28 0,16 0,6
6 0,64 1,28 0,16 20,0
9 0,64 1,28 0,04 60,0
14 1,28 1,28 0,08 0,2
15 0,16 1,28 0,16 0,2
16 0,04 1,28 0,16 NS
NS - tests with SM less than 5% were considered not to be successful. ..
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Discussion
These results confirm the presence of chloroquine-resistant
p. falciparum in the eastern Transvaal. No information is,
however, available concerning the in vivo response of the
same parasites to chloroquine. There was a wide range of
susceptibility to sulphadoxine/pyrimethamine (MICs ranged
from 0,2 to 60 J,lmoVI). The isolates fell into two distinct
groups, those with MICs < 1 J,lmoVI and those with MICs
~ 20 J,lmol/l. It was not possible to draw conclusions
regarding the Fansidar resistance status of these isolates as
the discriminatory MIC values for resistant isolates in the
WHO sUlphadoxine/pyrimethainine in vitro test have not yet
been determined. Various authors have found that resistant
and sensitive isolates can easily be distinguished by their
MICs"" and it is therefore possible that 2 isolates in this study
with MICs ~ 20 I1moVI may in fact be resistant to Fansidar.
Since all the cases were classified as local transmission by
the authorities, the results indicate that there is transmission
of chloroquine-resistant and possibly Fansidar-resistant P.
falciparum malaria in this region. These data are considered
important to the planning of malaria control strategies for the
area. Continued monitoring of the susceptibility to Fansidar
(both in vivo and in vitro) should be seen as a priority.
Immunity to malaria is known to shorten the duration of
individuarinfections and to enhance the effect of antimalarial
drugs!' Chloroquine may still have a role to play in malaria
control but resistance to this drug would pose a threat to
non-immune tourists travelling to this area.
As outlined earlier, chloroquine-resistant P. falciparum is
widespread in southern Africa. A large number of our malaria
cases are imported into the country (> 30%) (Department of
National Health and Population Development - notification
data) and it is therefore not surprising that chloroquine
resistance should be detected in our malarious areas.
Currently, the eastern Transvaal is still documented as a low-
risk area where chloroquine alone or no prophylaxis is
recommended.22 We believe that the eastern Transvaal
should be reclassified as a moderate to high-risk area
(mainly from November to May) where prophylaxis such as
chloroquine plus proguanil or mefloquine or doxycycline
should be recommended to tourists.
This study will continue in the next malaria season.
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Antimalarial measures -
type, sources of advice and
compliance among tourists
to Natal/KwaZulu
G. B. Wilken, L. Baker
Typical advice on antimalarial measures provided by
pharmacies as well as actual behaviour in this regard and
sources of advice accessed by tourists to northern Natal/
Kwazulu were canvassed by telephonic interviews with 70
pharmacies and 53 'care providers' (members of travel
parties). Doctors (26%) and phannacists (40%) were the
most commonly approached sources of antimalarial
advice. Professional recommendations frequently involved
chloroquine-based drugs (80% of recommended drugs),
despite the chloroqUine-resistant status of the study area.
Drug choice reflected the limited availability of new
alternatives to chloroquine at the time the study was
conducted, as well as ignorance of drug resistance in the
area Possible reasons for the inappropriate nature of many
of the reported recommendations, as well as an approach
to the dissemination of future prophylactic policy
documents, are discussed.
S Afr Med J 1994; 84: 395-398.
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